

Klisyri® (tirbanibulin) – New drug approval

- On December 15, 2020, <u>Athenex announced</u> the FDA approval of <u>Klisyri (tirbanibulin)</u>, for the topical treatment of actinic keratosis (AK) of the face or scalp.
- AK is a pre-cancerous skin lesion and is the second most common diagnosis made by dermatologists in the U.S. If left untreated, 10-15% of AK lesions will develop into skin cancers. Other treatment options for AK include cryotherapy, surgical removal of the lesion, or topical treatment with fluorouracil, imiquimod, or photodynamic therapy.
- Klisyri is a microtubule inhibitor. The mechanism of action of Klisyri for the topical treatment of AK is unknown.
- The efficacy of Klisyri was established in two double-blind, vehicle-controlled clinical studies
 conducted in 702 adult subjects with AK on the face or scalp. The primary efficacy endpoint was
 complete (100%) clearance of AK lesions in the treatment area, defined as the proportion of subjects
 at day 57 with no clinically visible AK lesions in the treatment area.
 - In study 1, 44% of Klisyri treated patients vs. 5% of vehicle treated patients achieved 100% clearance rates at day 57 (treatment difference: 40%; 95% CI: 31.6, 47.5).
 - In study 2, 54% of Klisyri treated patients vs. 13% of vehicle treated patients achieved 100% clearance rates at day 57 (treatment difference: 42%; 95% CI: 33.1, 50.7).
 - Of the 174 subjects treated with Klisyri who were followed, the recurrence rate at 12 months post-day 57 was 73%.
- Warnings and precautions for Klisyri include ophthalmic adverse reactions and local skin reactions.
- The most common adverse reactions (≥ 2%) with Klisyri use were local skin reactions, application site pruritus, and application site pain.
- Apply a sufficient amount of Klisyri to evenly cover up to 25 cm² treatment field on the face or scalp once daily for 5 consecutive days using one single-dose packet per application.
- Athenex plans to launch Klisyri in the first quarter of 2021. Klisyri will be available as a 1% ointment in a single-dose packet (2.5 mg tirbanibulin in 250 mg).



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

 $\mbox{RxNews}^{\tiny{\textcircled{\tiny{\scriptsize 0}}}}$ is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.